Rivaroxaban Viatris (previously Rivaroxaban Mylan)

Rivaroxaban Mylan is an anticoagulant medicine (a medicine that prevents blood clotting) used: - to treat deep vein thrombosis (DVT, a blood clot in a deep vein, usually in the leg) and pulmonary embolism (a clot in a blood vessel supplying the lungs), and to prevent DVT and pulmonary embolism from re-occurring in adults; - to prevent venous thromboembolism (VTE, the formation of blood clots in the veins) in adults who are undergoing surgery to replace a hip or knee; - to treat VTE and prevent VTE from re-occurring in children and adolescents aged less than 18 years weighing more than 30 kg; - to prevent stroke (caused by a clot in a blood vessel in the brain) and systemic embolism (a clot in other blood vessels) in adults with non-valvular atrial fibrillation (irregular rapid contractions of the upper chambers of the heart); - to prevent atherothrombotic events (such as heart attack, stroke or death from heart disease) in adults: - after an acute coronary syndrome, when it is used with an antiplatelet medicine (which prevents the formation of blood clots). Acute coronary syndrome consists of conditions such as unstable angina (a severe type of chest pain) and heart attack; - at high risk of ischaemic events (problems caused by restricted blood supply) who have coronary artery disease (disease caused by obstructed blood supply to the heart muscle) or peripheral artery disease (disease caused by defective blood flow in the arteries). It is used with aspirin. Rivaroxaban Mylan contains the active substance rivaroxaban and is a ‘generic medicine’. This means that Rivaroxaban Mylan contains the same active substance and works in the same way as a ‘reference medicine’ already authorised in the EU called Xarelto. For more information on generic medicines, see the question-and-answer document [here](/en/documents/medicine-qa/questions-answers-generic-medicines_en.pdf).